PROCASTAT

Welcome to the Brand page for “PROCASTAT”, which is offered here for Clinical medical reagents for use in gene therapy; pharmaceutical preparations, vaccines for use in gene therapy; therapeutic compositions containing liposome reagents or nucleic acid suitable for gene therapy for use in the treatment of cancer and auto-immune disorders; pharmaceutical preparations containing nucleic acids for use in the treatment of viral and bacterial infections, cancer, hiv and aids-related infections and bodily conditions associated with impaired immunosystems, single gene disorders, hemophilia, blood disorders, vascular disorders and disorders arising from inappropriate vascularization diseases of the nervous system, cardiac disorders, inflammatory and auto-immune diseases; pharmaceutical preparations and vaccines for use in the treatment of cancer, single gene disorders, hemophilia, blood disorders, vascular disorders and disorders arising from inappropriate vascularization, diseases of the nervous system, cardiac disorders, inflammatory and auto-immune diseases; enzymes and enzymatic preparations for medical use in the treatment of bacterial infections; retroviral vector preparations for medical use in the treatment of cancer; and chemotherapeutics for medical use;instruments and apparatus for the administration of gene therapy products, vials, syringes, injectors, catheters and tubes; and surgical and medical apparatus and instruments, scalpels, knives, forceps and surgical clips;.

Its status is currently believed to be active. Its class is unavailable. “PROCASTAT” is believed to be currently owned by “Oxford BioMedica plc”.